Immunization with an experimental anti-cocaine vaccine resulted in a substantial reduction in cocaine use in 38 percent of vaccinated patients in a clinical trial supported by the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health. The study, published in the October issue of Archives of General Psychiatry, is the first successful, placebo-controlled demonstration of a vaccine against an illicit drug of abuse.
For more information on this ground-breaking finding, please see below.
http://www.drugabuse.gov/newsroom/09/NR10-05.html
The vaccine is not ready for widespread use yet. But this could become one way for PSI to do product-based drug demand reduction, wherever cocaine use is prevalent and widespread.
Rob
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment